Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach

Drug Metabolism and Disposition

Volumn 39, Issue 5, 2011, Pages 820-829

  Deguchi, Tsuneo ^a   Watanabe, Nobuaki ^a   Kurihara, Atsushi ^a   Igeta, Katsuhiro ^a   Ikenaga, Hidenori ^a   Fusegawa, Keiichi ^a   Suzuki, Norio ^a   Murata, Shinji ^a   Furuta, Yoshitake ^a   Iwasaki, Masaru ^a   Okazaki, Osamu ^a   Izumi, Takashi ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DICLOFENAC; FUROSEMIDE; GEMFIBROZIL; GLUCURONOSYLTRANSFERASE; IMIPENEM; INDOMETACIN; KETOPROFEN; LEVOFLOXACIN; LORAZEPAM; MYCOPHENOLIC ACID; RALOXIFENE; TELMISARTAN; ZIDOVUDINE;

ACCURACY; ALLOMETRY; ANIMAL EXPERIMENT; ARTICLE; BILE DUCT; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOG; DRUG GLUCURONIDATION; DRUG METABOLISM; HALF LIFE TIME; HAPLORHINI; MALE; MOUSE; NONHUMAN; PLASMA CLEARANCE; PREDICTION; PRIORITY JOURNAL; RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; CYTOCHROME P-450 ENZYME SYSTEM; DOGS; DRUG EVALUATION, PRECLINICAL; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HALF-LIFE; HUMANS; MACACA FASCICULARIS; MALE; MICE; PHARMACEUTICAL PREPARATIONS; PREDICTIVE VALUE OF TESTS; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY;

ANIMALIA; CANIS FAMILIARIS; MUS; RATTUS;

EID: 79955001395     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.037457     Document Type: Article

References (38)

1. Alván G, Orme M, Bertilsson L, Ekstrand R, and Palmír L (1975) Pharmacokinetics of indomethacin. Clin Pharmacol Ther 18:364-373.
2. Bullingham RE, Nicholls AJ, and Kamm BR (1998) Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 34:429-455. (Pubitemid 28273453)
3. Chien SC, Rogge MC, Gisclon LG, Curtin C, Wong F, Natarajan J, Williams RR, Fowler CL, Cheung WK, and Chow AT (1997) Pharmacokinetic profile of levofloxacin following oncedaily 500-milligram oral or intravenous doses. Antimicrob Agents Chemother 41:2256-2260. (Pubitemid 27422222)
4. Collins JM (2001) Inter-species differences in drug properties. Chem Biol Interact 134:237-242. (Pubitemid 32406146)
5. Cubitt HE, Houston JB, and Galetin A (2009) Relative importance of intestinal and hepatic glucuronidation-impact on the prediction of drug clearance. Pharm Res 26:1073-1083.
6. de Miranda P, Burnette TC, and Good SS (1990) Tissue distribution and metabolic disposition of zidovudine in rats. Drug Metab Dispos 18:315-320. (Pubitemid 20174244)
7. Duggan DE, Hogans AF, Kwan KC, and McMahon FG (1972) The metabolism of indomethacin in man. J Pharmacol Exp Ther 181:563-575.
8. Fish DN and Chow AT (1997) The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet 32:101-119. (Pubitemid 27104410)
9. Greenblatt DJ (1981) Clinical pharmacokinetics of oxazepam and lorazepam. Clin Pharmacokinet 6:89-105. (Pubitemid 12212452)
10. Greenblatt DJ, Divoll M, Harmatz JS, and Shader RI (1982) Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular, and oral lorazepam. J Pharm Sci 71:248-252. (Pubitemid 12112857)
11. Heringa M (2003) Review on raloxifene: Profile of a selective estrogen receptor modulator. Int J Clin Pharmacol Ther 41:331-345. (Pubitemid 36980563)
12. Hosea NA, Collard WT, Cole S, Maurer TS, Fang RX, Jones H, Kakar SM, Nakai Y, Smith BJ, Webster R, et al. (2009) Prediction of human pharmacokinetics from preclinical information: Comparative accuracy of quantitative prediction approaches. J Clin Pharmacol 49:513-533.
13. Izumi T, Enomoto S, Hosiyama K, Sasahara K, Shibukawa A, Nakagawa T, and Sugiyama Y (1996) Prediction of the human pharmacokinetics of troglitazone, a new and extensively metabolized antidiabetic agent, after oral administration, with an animal scale-up approach. J Pharmacol Exp Ther 277:1630-1641. (Pubitemid 27167181)
14. Jamali F and Brocks DR (1990) Clinical pharmacokinetics of ketoprofen and its enantiomers. Clin Pharmacokinet 19:197-217. (Pubitemid 20281450)
15. Kilford PJ, Stringer R, Sohal B, Houston JB, and Galetin A (2009) Prediction of drug clearance by glucuronidation from in vitro data: Use of combined cytochrome P450 and UDPglucuronosyltransferase cofactors in alamethicin-activated human liver microsomes. Drug Metab Dispos 37:82-89.
16. Kochansky CJ, Xia YQ, Wang S, Cato B, Creighton M, Vincent SH, Franklin RB, and Reed JR (2005) Species differences in the elimination of a peroxisome proliferator-activated receptor agonist highlighted by oxidative metabolism of its acyl glucuronide. Drug Metab Dispos 33:1894-1904. (Pubitemid 41697276)
17. Mackenzie PI, Bock KW, Burchell B, Guillemette C, Ikushiro S, Iyanagi T, Miners JO, Owens IS, and Nebert DW (2005) Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 15:677-685. (Pubitemid 41345319)
18. McCrindle JL, Li Kam Wa TC, Barron W, and Prescott LF (1996) Effect of food on the absorption of frusemide and bumetanide in man. Br J Clin Pharmacol 42:743-746. (Pubitemid 26417616)
19. Miles KK, Stern ST, Smith PC, Kessler FK, Ali S, and Ritter JK (2005) An investigation of human and rat liver microsomal mycophenolic acid glucuronidation: Evidence for a principal role of UGT1A enzymes and species differences in UGT1A specificity. Drug Metab Dispos 33:1513-1520. (Pubitemid 41324000)
20. Miners JO, Knights KM, Houston JB, and Mackenzie PI (2006) In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: Pitfalls and promises. Biochem Pharmacol 71:1531-1539.
21. Moore KH, Raasch RH, Brouwer KL, Opheim K, Cheeseman SH, Eyster E, Lemon SM, and van der Horst CM (1995) Pharmacokinetics and bioavailability of zidovudine and its glucuronidated metabolite in patients with human immunodeficiency virus infection and hepatic disease (AIDS Clinical Trials Group protocol 062). Antimicrob Agents Chemother 39:2732-2737.
22. Nakai D, Kumamoto K, Sakikawa C, Kosaka T, and Tokui T (2004) Evaluation of the protein binding ratio of drugs by a micro-scale ultracentrifugation method. J Pharm Sci 93:847-854. (Pubitemid 38420397)
23. Obach RS, Lombardo F, and Waters NJ (2008) Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab Dispos 36: 1385-1405. (Pubitemid 351929323)
24. Ruelius HW (1978) Comparative metabolism of lorazepam in man and four animal species. J Clin Psychiatry 39:11-15. (Pubitemid 9006065)
25. Sawamura R, Okudaira N, Watanabe K, Murai T, Kobayashi Y, Tachibana M, Ohnuki T, Masuda K, Honma H, Kurihara A, et al. (2010) Predictability of idiosyncratic drug toxicity risk for carboxylic acid-containing drugs based on the chemical stability of acyl glucuronide. Drug Metab Dispos 38:1857-1864.
26. Shibata Y, Takahashi H, Chiba M, and Ishii Y (2002) Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: An application of serum incubation method. Drug Metab Dispos 30:892-896. (Pubitemid 34815418)
27. Soars MG, Burchell B, and Riley RJ (2002) In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. J Pharmacol Exp Ther 301:382-390. (Pubitemid 34250317)
28. Stangier J, Schmid J, Türck D, Switek H, Verhagen A, Peeters PA, van Marle SP, Tamminga WJ, Sollie FA, and Jonkman JH (2000a) Absorption, metabolism, and excretion of intravenously and orally administered [14C]telmisartan in healthy volunteers. J Clin Pharmacol 40:1312-1322.
29. Stangier J, Su CA, and Roth W (2000b) Pharmacokinetics of orally and intravenously admin-istered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res 28:149-167. (Pubitemid 30648951)
30. Stierlin H, Faigle JW, Sallmann A, Küng W, Richter WJ, Kriemler HP, Alt KO, and Winkler T (1979) Biotransformation of diclofenac sodium (Voltaren) in animals and in man. I. Isolation and identification of principal metabolites. Xenobiotica 9:601-610. (Pubitemid 10167099)
31. Tang H, Hussain A, Leal M, Mayersohn M, and Fluhler E (2007) Interspecies prediction of human drug clearance based on scaling data from one or two animal species. Drug Metab Dispos 35:1886-1893. (Pubitemid 47481583)
32. Tang H and Mayersohn M (2005) A novel model for prediction of human drug clearance by allometric scaling. Drug Metab Dispos 33:1297-1303. (Pubitemid 41196972)
33. Tanimura H, Ohnishi H, Okamura T, Uenishi M, Ichimiya G, Kobayashi Y, Aoki Y, Oka S, Yamamoto S, and Shimada K (1992) [Chemotherapy of biliary tract infections (XXXVII). Excretion into bile and gallbladder tissue levels of levofloxacin and its clinical effect in biliary tract infections]. Jpn J Antibiot 45:557-568.
34. Todd PA and Ward A (1988) Gemfibrozil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dyslipidaemia. Drugs 36:314-339.
35. Ward KW and Smith BR (2004) A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance. Drug Metab Dispos 32:603-611. (Pubitemid 38668152)
36. White CR and Seymour RS (2005) Allometric scaling of mammalian metabolism. J Exp Biol 208:1611-1619. (Pubitemid 40697609)
37. Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, and Ball SE (2004) Drug-drug interactions for UDP- glucuronosyltransferase substrates: A pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 32:1201-1208. (Pubitemid 39410902)
38. Willis JV, Kendall MJ, Flinn RM, Thornhill DP, and Welling PG (1979) The pharmacokinetics of diclofenac sodium following intravenous and oral administration. Eur J Clin Pharmacol 16:405-410. (Pubitemid 10173752)